Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Dermatology Online Journal
|
April 28, 2006
Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept
Marianne T Sweetser, James Woodworth, Suzanne Swan, et al.
JIMD Reports
|
July 8, 2024
Elevated homocysteine is negatively correlated with plasma cystathionine β-synthase activity in givosiran-treated patients
Mark A Keibler, Gautham V Sridharan, Marianne T Sweetser, et al.
Journal of Drugs in Dermatology : JDD
|
July 27, 2006
Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study
John Y M Koo, Jerry Bagel, Marianne T Sweetser, et al.
Journal of the Neurological Sciences
|
April 16, 2014
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
Michael Kaufman, Gabriel Pardo, Howard Rossman, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
December 3, 2023
A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort
Ming-Jen Lee, Hung-Chou Kuo, Lin-Na Chou, et al.
Journal of Clinical Pharmacology
|
July 20, 2019
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
Xiaoping Zhang, Varun Goel, Husain Attarwala, et al.
Arthritis and Rheumatism
|
March 2, 2011
Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial
Maria W Greenwald, William J Shergy, Jeffrey L Kaine, et al.
Expert Opinion on Pharmacotherapy
|
August 27, 2013
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
Eva Havrdova, Michael Hutchinson, Nuwan C Kurukulasuriya, et al.
Molecular Therapy. Nucleic Acids
|
July 21, 2025
Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Martha Grogan, Farooq H Sheikh, Brett W Sperry, et al.
European Journal of Neurology
|
July 11, 2024
Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
Celine Labeyrie, Madeline Merkel, Sakshi Sethi, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Dermatology Online Journal
|
April 28, 2006
Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept
Marianne T Sweetser, James Woodworth, Suzanne Swan, et al.
JIMD Reports
|
July 8, 2024
Elevated homocysteine is negatively correlated with plasma cystathionine β-synthase activity in givosiran-treated patients
Mark A Keibler, Gautham V Sridharan, Marianne T Sweetser, et al.
Journal of Drugs in Dermatology : JDD
|
July 27, 2006
Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study
John Y M Koo, Jerry Bagel, Marianne T Sweetser, et al.
Journal of the Neurological Sciences
|
April 16, 2014
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
Michael Kaufman, Gabriel Pardo, Howard Rossman, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
December 3, 2023
A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort
Ming-Jen Lee, Hung-Chou Kuo, Lin-Na Chou, et al.
Journal of Clinical Pharmacology
|
July 20, 2019
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
Xiaoping Zhang, Varun Goel, Husain Attarwala, et al.
Arthritis and Rheumatism
|
March 2, 2011
Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial
Maria W Greenwald, William J Shergy, Jeffrey L Kaine, et al.
Expert Opinion on Pharmacotherapy
|
August 27, 2013
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
Eva Havrdova, Michael Hutchinson, Nuwan C Kurukulasuriya, et al.
Molecular Therapy. Nucleic Acids
|
July 21, 2025
Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Martha Grogan, Farooq H Sheikh, Brett W Sperry, et al.
European Journal of Neurology
|
July 11, 2024
Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
Celine Labeyrie, Madeline Merkel, Sakshi Sethi, et al.
Page
of 4